Navigation Links
New Pharmaxis Board Appointment
Date:6/23/2008

SYDNEY, Australia, June 23 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of senior Australian pharmaceutical executive Will Delaat to its board of directors.

Mr Delaat has 35 years experience in the global pharmaceutical industry, most recently as the managing director of the Australian subsidiary of Merck & Co., a position he held from 1997 until his recent retirement.

During his career Mr Delaat has held executive positions in both Europe and Australia for Merck and AstraZeneca. Mr Delaat is experienced in sales and marketing and has been responsible for international product launches and commercialisation of respiratory products.

Mr Delaat also serves the pharmaceutical industry in important representative roles. He is chairman of the Australian pharmaceutical industry's peak body, Medicines Australia, and is chairman of the Pharmaceuticals Industry Council.

''Will Delaat is one of Australia's pharmaceutical industry leaders'' said Pharmaxis Chairman, Denis Hanley. ''The Pharmaxis board will benefit from his invaluable skills and experience.''

In accepting the board director position Mr Delaat said: ''Pharmaxis holds enormous promise and I look forward to being part of its effort to bring innovative medicines to patients world-wide."

For information on all Pharmaxis Board members, go to http://tinyurl.com/3s4g2n .

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements incl
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Pharmaxis Aridol Authorised for Sale in Germany
2. Pharmaxis First Steps into China
3. Pharmaxis to Apply to Market Bronchitol in Australia
4. Pharmaxis Investor Conference Call
5. Pharmaxis Aridol Gains First Asian Approval
6. Pharmaxis Appoints Portuguese Distributor for Aridol
7. Pharmaxis Closes Share Purchase Plan
8. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
9. Phase III Trial Finds Pharmaxis Bronchitol Effective
10. Corgenix Expands Scientific Advisory Board
11. Spring Point Project Names New Members to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
(Date:5/21/2013)... -- Personal Genome Diagnostics Inc. (PGDx), today announced that ... in genomic analysis of defined cancer subtypes to ... Medicines.  PGDx is an innovator in conducting patient-specific ... and Blueprint Medicines is an expert in developing ... patient population. "This collaboration brings together ...
(Date:5/21/2013)... May 21, 2013 Revolutionary Science, the ... colony counter, announced today that they have expanded their ... , the IncuCount, IntelliCount, InCount and ImpressCount. These ... are especially useful in food microbiology and pharmaceutical manufacturing. ... updated look. A bright white enclosure with jet ...
(Date:5/21/2013)... Inflamax scientists worked closely with internationally ... the study, which will provide critical insight into ... in the study of allergy treatments, the Environmental ... models. Although both the models are well recognized ... direct comparison between the allergic responses evoked by ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... trial indicate statistically significant reduction in recurrences ... ... JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/,-- Medarex, Inc. (Nasdaq: MEDX ... Medical School (UMMS) today,announced that a Phase 2 trial of an ...
... Cepheid (Nasdaq:,CPHD) today announced that it ... Stretton Scientific Limited, a privately held distributor ... in,Stretton, England. Stretton Scientific currently distributes Cepheid,s,SmartCycler(R) ... products, to,a broad group of medical customers ...
... financial guidance through second quarter of 2009 - ... - Conference ... BRANFORD, Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRGN ), today ... the three month period ended September 30, 2008, CuraGen,utilized $3.6 million ...
Cached Biology Technology:Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 2Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 3Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 4Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 5Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 6Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 2Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 3CuraGen Reports Third Quarter 2008 Financial Results 2CuraGen Reports Third Quarter 2008 Financial Results 3CuraGen Reports Third Quarter 2008 Financial Results 4CuraGen Reports Third Quarter 2008 Financial Results 5CuraGen Reports Third Quarter 2008 Financial Results 6
(Date:5/21/2013)... most deadly when they metastasize and spread tumors throughout ... becomes very difficult for doctors to locate and treat ... the University of Missouri have found a way to ... they may be in the body. Michael Lewis, an ... Veterinary Medicine, says being able to target secondary tumors ...
(Date:5/21/2013)... in pharmacies and health stores, phosphatidylserine is a ... soy. Proven to improve cognition and slow memory ... experiencing memory impairment. Now a team headed by ... Tel Aviv University,s Department of Human Molecular ... improves the functioning of genes involved in degenerative ...
(Date:5/21/2013)... in shape is an uphill battle? Try staying fit ... weightlessness withers muscle and bone. , That,s the challenge ... with a new three-year, $1.2 million grant from NASA. ... during multiyear exploratory missions. , "You could give astronauts ... can,t get them to stick to it, it isn,t ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2Fueling fitness on the final frontier 2
... birds often choose their mates based on fancy feathers. ... likely to follow their noses to the right mate. ... Harvard researcher Katherine McAuliffe, whose review of evidence for ... issue of The Quarterly Review of Biology . ...
... that belongs to the oldest living family of jawed vertebrates, ... discovery, published in the March 2009 issue of Genome ... evolved in early vertebrates over the last 450 million years ... vertebrate like the elephant shark had the potential for color ...
... a novel regulator of p53, an important protein that safeguards ... March 17, 2009 issue of the journal Genes & ... this microRNA keeps the level of p53 low to avoid ... damaged, the microRNA level is reduced to allow an increase ...
Cached Biology News:Female mammals follow their noses to the right mates 2Elephant shark genome sequence leads to discovery of color perception in deep-sea fish 2Regulatory molecule for tumor formation or suppression identified by Singapore, US researchers 2
... 9 oligodeoxynucleotides are random ... at the 5' end ... Fluor dyes and they ... microarray spot morphology, hybridization ...
Mycoplasma tested...
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
... Our fastest automated perfusion system. For ... perfusion, physiology, biophysics, electrochemistry, or general ... with 1.5-4 millisecond accuracy Run ... Microprocessor-based for accuracy and flexibility ...
Biology Products: